Literature DB >> 23066331

Vague relationship between alcohol consumption and metabolic syndrome in nonobese people.

Kei Nakajima, Masafumi Saito.   

Abstract

Fatty liver, including non-alcoholic fatty liver disease, is closely associated with metabolic syndrome (MS). Thus, the presence of fatty liver without MS in some conditions may be clinically important. Many studies have shown that compared with no or occasional alcohol intake, moderate alcohol consumption is associated with lower prevalence rates of hypertension and type 2 diabetes, and lower levels of circulating C-reactive protein, a valuable marker for MS and insulin resistance. Considering these findings, light to moderate alcohol consumption has theoretical benefits on fatty liver and MS. Fatty liver, including non-alcoholic fatty liver disease, may be more clinically important than MS, particularly in non-obese individuals, because fatty liver can develop before MS in several conditions, such as regular alcohol consumers. Furthermore, most of the currently used MS criteria are unable to detect "true MS" because of variations in multiple factors such as age, height, medications, and complications.

Entities:  

Keywords:  Adult treatment panel III; Alcohol consumption; Metabolic syndrome; Non-alcoholic fatty liver disease

Mesh:

Year:  2012        PMID: 23066331      PMCID: PMC3468869          DOI: 10.3748/wjg.v18.i37.5315

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  Relation between alcohol consumption and C-reactive protein levels in the adult US population.

Authors:  Scott H Stewart; Arch G Mainous; Greg Gilbert
Journal:  J Am Board Fam Pract       Date:  2002 Nov-Dec

2.  Alcohol deranges hepatic lipid metabolism via altered transcriptional regulation.

Authors:  David W Crabb
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

3.  De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption.

Authors:  S Q Siler; R A Neese; M K Hellerstein
Journal:  Am J Clin Nutr       Date:  1999-11       Impact factor: 7.045

Review 4.  Alcohol consumption and type 2 diabetes Meta-analysis of epidemiological studies indicates a U-shaped relationship.

Authors:  S Carlsson; N Hammar; V Grill
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

5.  Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein.

Authors:  Shaista Malik; Nathan D Wong; Stanley Franklin; Jose Pio; Carol Fairchild; Roland Chen
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

6.  Nutritional deficiencies in chronic alcoholics: relation to dietary intake and alcohol consumption.

Authors:  L Glória; M Cravo; M E Camilo; M Resende; J N Cardoso; A G Oliveira; C N Leitão; F C Mira
Journal:  Am J Gastroenterol       Date:  1997-03       Impact factor: 10.864

7.  Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults.

Authors:  Hae Jin Kim; Hyeong Jin Kim; Kwang Eun Lee; Dae Jung Kim; Soo Kyung Kim; Chul Woo Ahn; Sung-Kil Lim; Kyung Rae Kim; Hyun Chul Lee; Kap Bum Huh; Bong Soo Cha
Journal:  Arch Intern Med       Date:  2004-10-25

8.  Protective effect of alcohol consumption for fatty liver but not metabolic syndrome.

Authors:  Masahide Hamaguchi; Takao Kojima; Akihiro Ohbora; Noriyuki Takeda; Michiaki Fukui; Takahiro Kato
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

9.  Alcohol consumption and plasma concentration of C-reactive protein.

Authors:  Michelle A Albert; Robert J Glynn; Paul M Ridker
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

10.  C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.

Authors:  Paul M Ridker; Julie E Buring; Nancy R Cook; Nader Rifai
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.